Handelsavisen
prelaunch
Companies Healthcare 3662.HK
36
3662.HK HKEX Healthcare Facilities & Services

Starjoy Wellness and Travel Co Ltd

HK$0,32
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
228,8M HKD
P/E
3,9x
EV / Rev
Div yield
0,00 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Starjoy Wellness and Travel Co Ltd operates in the healthcare facilities and services industry, providing wellness and travel-related services to its customers.

Business. Starjoy Wellness and Travel Co Ltd (3662.HK) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
SELL1 analysts
0 buy0 hold1 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Sell
Buy0
Hold0
Sell1
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
3,9x
P/E
Analysts
Sell
1 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 3662.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 3662.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Starjoy Wellness and Travel Co Ltd (3662.HK) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    Starjoy Wellness and Travel Co Ltd has a market capitalization of 203.35 million CNY, with a market price of 0.28 CNY per share. The company has 726.25 million shares outstanding, with no dilution from potential share issuance as the diluted and basic shares are equal. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company's profitability and returns are not available for comparison against industry_config preferred metrics or cohort medians, as no relevant financial data is provided. This lack of data limits the ability to assess its performance relative to industry benchmarks.

    Segment and geographic exposure details are not disclosed in the available data, making it difficult to evaluate revenue concentration or geographic diversification. The company's business model and customer base remain opaque without further segment-level information.

    Growth trajectory is also unclear, as no outlook numeric deltas or revenue history are provided. Analyst estimates suggest a single sell recommendation, with no strong buy, buy, or hold ratings, indicating a generally negative sentiment among analysts.

    Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The low dilution risk is a positive, but the lack of financial transparency remains a concern.

    Recent events and filings are not detailed in the available data, so no specific recent developments can be reported. The absence of disclosed events or transcripts limits the ability to assess the company's current strategic direction or operational performance.

    Key takeaways
    • The company has a low market capitalization and no dilution from share issuance.
    • Analyst sentiment is negative, with one sell recommendation and no buy or strong buy ratings.
    • Liquidity risk could not be assessed due to missing balance-sheet data.
    • No segment or geographic exposure details are available, limiting visibility into revenue concentration.
    • Growth trajectory and performance metrics are not disclosed, making it difficult to evaluate future potential.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-03-27
    FY 2024 · Full-year highlights

    Revenue ¥1.36B, −13,3% YoY; Operating income −42,9% YoY.

    Revenue¥1.36B−13,3 % YoY
    Operating income¥115.7M−42,9 % YoY
    Net income¥96.2M−38,8 % YoY
    Free cash flow¥74.2M−54,5 % YoY
    EPS
    Operating cash flow¥140.3M+32,4 % YoY
    Financials
    Income statement
    Revenue¥1.36B
    Gross profit¥385.0M
    Operating income¥115.7M
    Net income¥96.2M
    Margins
    Gross margin28.4%
    Operating margin8.5%
    Net margin7.1%
    FCF margin5.5%
    Balance sheet
    Total assets¥2.36B
    Total liabilities¥1.16B
    Total equity¥1.20B
    Cash & equivalents
    Long-term debt¥81.7M
    Cash flow
    Operating cash flow¥140.3M
    CapEx-¥32.7M
    Free cash flow¥74.2M
    SBC
    P&L flow · revenue → net income
    Revenue ¥1.36BOperating costs ¥1.24BTax ¥19.5MNet income ¥96.2M
    Highlights
    • Revenue ¥1.36B, −13,3% YoY
    • Operating income −42,9% YoY
    • Net income −38,8% YoY
    • Free cash flow −54,5% YoY
    • Net margin 7.1%

    Valuation FY

    Market price
    HK$0,32
    Market cap
    HK$203.3M
    Enterprise value
    P/E
    3.9x
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold0
    Sell1
    Strong sell0

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Starjoy Wellness and Travel Co Ltd Market data — financials · 2026-05-26
    • Starjoy Wellness and Travel Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    3662.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-03-27 16:00 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 1.36B · Net CNY 96.2M
    2023-05-17 16:42 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 1.56B · Net CNY 157.1M
    2021-03-29 20:16 UTCEARNINGSAnnual results — FY 2021 Revenue CNY 1.94B · Net CNY -190.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage